Long‐term follow‐up of patients with NAFLD and elevated liver enzymes

By M. Ekstedt, L. Franzén, U. Mathiesen, L. Thorelius, M. Holmqvist, G. Bodemar, S. Kechagias. Hepatology, 2006

2,374 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Surgery

View Paper: https://www.semanticscholar.org/paper/cb4492db00e58c855d5d0860e636cd0155f59413

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

In Epidemiology

In Surgery

Citations in the corpus

The Plasma Lipidomic Signature of Nonalcoholic Steatohepatitis (2009, methodology): “A total of three groups were studied: (1) lean normal controls; (2) NAFL; and (3) NASH.”
Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD. (2017, methodology): “NAFLD patients have an increased all-cause and liver related mortality [8, 9].”
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management. (2015, background): “In general, it is thought that fibrosis progression in patients with NAFL is uncommon, whereas NASH progresses more frequently [18,19,21–25].”
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers (2007, methodology): “The diagnosis of NAFLD was based on the following criteria: (1) elevated aminotransferases [aspartate aminotransferase (AST) or alanine aminotransferase (ALT)]; (2) appropriate exclusion of liver disease of other origin including alcoholinduced or drug-induced liver disease, autoimmune or viral hepa”
Pathogenesis of non-alcoholic fatty liver disease (2009, background): “Structural mitochondrial abnormalities 71 and a reduction in mitochondrial respiratory chain activity have been observed in human studies of NASH.”
Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality (2011, background): “In summary, our data confirm that patients with NASH are at high risk for LRM.(1-14,21-30) We have also shown that a certain degree of agreement exists between all four sets of pathologic criteria for NASH.”
Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years (2010, background): “Increased mortality and liver-related complications are mainly seen in patients with NASH.7 On the other hand, simple steatosis is believed to be benign and non-progressive.”
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases (2018, background): “Management of Cardiovascular Disease and Dyslipidemia There is a strong association between NAFLD and increased risk of CVD events and mortality that withstands correction for traditional CVD risk factors (218,219).”
Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults (2011, background): “7 years of follow-up but not in patients with simple steatosis.(107)”
A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “Liver-related mortality is increased 9–10-fold [51,71] with cirrhosis an independent cause of death ranking 3rd vs.”